Predicting 1p/19q codeletion status using diffusion-,susceptibility-,perfusion-weighted,and conventional MRI in IDH-mutant lower-grade gliomas

Abstract

Background

Isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas (LGGs) are further classified into two classes: with and without 1p/19q codeletion. IDH-mutant and 1p/19q codeleted LGGs have better prognosis compared with IDH-mutant and 1p/19q non-codeleted LGGs.

Purpose

To evaluate conventional magnetic resonance imaging (cMRI), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) for predicting 1p/19q codeletion status of IDH-mutant LGGs.

Material and Methods

We retrospectively reviewed cMRI, DWI, SWI, and DSC-PWI in 142 cases of IDH mutant LGGs with known 1p/19q codeletion status. Features of cMRI, relative ADC (rADC), intratumoral susceptibility signals (ITSSs), and the value of relative cerebral blood volume (rCBV) were compared between IDH-mutant LGGs with and without 1p/19q codeletion. Receiver operating characteristic curve and logistic regression were used to determine diagnostic performances.

Results

IDH-mutant and 1p/19q non-codeleted LGGs tended to present with the T2/FLAIR mismatch sign and distinct borders (P < 0.001 and P = 0.038, respectively). Parameters of rADC, ITSSs, and rCBV_max were significantly different between the 1p/19q codeleted and 1p/19q non-codeleted groups (P < 0.001, P = 0.017, and P < 0.001, respectively). A combination of cMRI, SWI, DWI, and DSC-PWI for predicting 1p/19q codeletion status in IDH-mutant LGGs resulted in a sensitivity, specificity, positive predictive value, negative predictive value, and an AUC of 80.36%, 78.57%, 83.30%, 75.00%, and 0.88, respectively.

Conclusion

1p/19q codeletion status of IDH-mutant LGGs can be stratified using cMRI and advanced MRI techniques, including DWI, SWI, and DSC-PWI. A combination of cMRI, rADC, ITSSs, and rCBV_max may improve the diagnostic performance for predicting 1p/19q codeletion status.

Keywords

1p/19q codeletion lower-grade gliomas T2/FLAIR mismatch sign diffusion-weighted imaging susceptibility-weighted imaging dynamic susceptibility contrast perfusion-weighted imaging

Get full access to this article

View all access options for this article.

References

Louis

Perry

Reifenberger

, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131:803–820.

Appin

, Brat DJ Molecular genetics of gliomas. Cancer J 2014; 20:66–72.

Brat

Verhaak

Aldape

, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372:2481–2498.

Den Bent

MJV

Brandes

Taphoorn

MJB

, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 2013; 31:344–350.

Chamberlain

Born

DE.

Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors. J Neurooncol 2015; 125:249–251.

Mj VDB. Chemotherapy for low-grade glioma: when, for whom, which regimen?

Curr Opin Neurol 2015; 28:633–938.

Kickingereder

Sahm

Radbruch

, et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 2015; 5:16238.

Leu

Ott

Lai

, et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol 2017; 134:177–188.

Le Bihan

Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003; 4:469–480.

10.

Svolos

Tsolaki

Kapsalaki

, et al. Investigating brain tumor differentiation with diffusion and perfusion metrics at 3T MRI using pattern recognition techniques. Magn Reson Imaging 2013; 31:1567–1577.

11.

Sehgal

Delproposto

Haacke

, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22:439–450.

12.

Zhang

Zhao

Guo

, et al. Application of susceptibility weighted imaging in revealing intratumoral blood products and grading gliomas. J Radiol 2010; 91:485–490.

13.

Jain

Gutierrez

Narang

, et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol 2011; 32:388–394.

14.

Chawla

Krejza

Vossough

, et al. Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy. AJNR Am J Neuroradiol 2013; 34:1542–1549.

15.

Tan

Xiong

Huang

, et al. Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 2017; 45:492–499.

16.

Fellah

Caudal

De Paula

, et al.

Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?

AJNR Am J Neuroradiol 2013; 34:1326–1333.

17.

Law

Brodsky

Babb

, et al. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging 2007; 25:1113–1119.

18.

Kapoor

Gocke

Chawla

, et al. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol 2009; 92:373–386.

19.

Jenkinson

du Plessis

Smith

, et al. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 2006; 129:1884–1891.

20.

Lasocki

Gaillard

MRI Features Can Predict 1p/19q Status in Intracranial Gliomas. AJNR Am J Neuroradiol 2018; 39:687–692.

21.

Patel

Poisson

Brat

,et al . T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. Clin Cancer Res 2017; 23:6078–6085.

22.

Park

Kim

Jahng

, et al. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009; 30:1402–1408.

23.

Boxerman

Shiroishi

Ellingson

, et al. Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice. Magn Reson Imaging C 2016; 24:649–670.

24.

Batchala

Muttikkal

TJE

. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas. AJNR Am J Neuroradiol 2019; 40:426–432.

25.

Sonoda

Shibahara

Kawaguchi

, et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015; 32:99–104.

26.

Johnson

, Diehn FE. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. AJNR Am J Neuroradiol 2017; 38:678–684.

27.

Xiong

Tan

Wen

, et al. Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. Eur Radiol 2016; 26:1705–1715.

28.

Reyes-Botero

Dehais

Idbaih

, et al. Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 2014; 16:662–670.

29.

Peng

Yishuang

Kaizhou

, et al. Conventional Magnetic Resonance Features for Predicting 1p19q Codeletion Status of World Health Organization Grade II and III Diffuse Gliomas. J Comput Assist Tomogr 2019; 43:269–276.

30.

Tay

Tsui

Phal

, et al. MR imaging characteristics of protoplasmic astrocytomas. Neuroradiology 2011; 53:405–411.

31.

Jenkinson

Smith

Brodbelt

, et al. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007; 26:1405–1412.

32.

Park

Han

Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas. AJNR Am J Neuroradiol 2018; 39:37–42.

33.

Kanazawa

Fujiwara

Takahashi

, et al. Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas. Neurosurg Rev 2019; 42:433–441.

34.

Jager

Waldman

Benton

, et al. Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 2005; 26:274–278.

35.

Godfraind

Rousseau

Ruchoux

, et al. Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 2003; 29:462–471.

36.

Choi

Ganji

DeBerardinis

, et al . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012; 18:624–629.

37.

Chang

Bai

Zhou

, et al. Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clin Cancer Res 2018; 24:1073–1081.

38.

Metellus

Coulibaly

Colin

, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010; 120:719–729.